

	 STUDIO	METABOLISM, ALCOHOL & TOXICITY	BASIC SCIENCE
9:00 - 10:00	OPENING CEREMONY		
10:00 - 10:45		PGC: Lifestyle and the liver - Non-alcoholic fatty liver disease	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Introduction and overview
11:15 - 11:30		PGC: Lifestyle and the liver - Impact of physical activity and diet on liver disease	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Artificial intelligence
11:30 - 12:30	EASL LUNCH TALK: NAFLD management - Why do so many drugs fail?		
12:45 - 13:45		PGC: Lifestyle and the liver - Nutritional and behavioural patterns affecting the liver	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Omics applications
14:00 -15:00		PGC: Lifestyle and the liver - Alcohol related liver disease	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Single-cell assessments
15:30 - 16:30		PGC: Lifestyle and the liver - Drugs and xenobiotic misuse and liver toxicity	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Emerging technologies
16:45 - 17:45		PGC: Lifestyle and the liver - Multidisciplinary outpatient approach to NAFLD and ALD	BASIC SCIENCE SEMINAR: Artificial intelligence, “omics” and big data in liver research - Clinical application
18:00 - 18:30		PGC: Lifestyle and the liver - State-of-the-Art lecture: Obesity: the public health approach	
19:00 - 20:00	EASL AFTERWORK ROUNDTABLE: How Deep learning and Artificial intelligence impact the future of hepatology research	INDUSTRY SATELLITE SYMPOSIA	
20:00 - 20:30			

	STUDIO	GENERAL HEPATOLOGY		VIRAL HEPATITIS	LIVER TUMOURS	CIRRHOSIS & COMPLICATIONS	IMMUNE-MEDIATED AND CHOLESTATIS	METABOLISM, ALCOHOL & TOXICITY		BASIC SCIENCE	MEET THE EXPERTS									
8:00 - 8:30		RTT: Vascular liver diseases - Focal lesions	HOT TOPICS IN LIVER TRANSPLANTATION I: The patient on the waiting list - Identifying the window of opportunity	RTT: Understanding immunological and virologic responses in the liver to cure HBV infections	RTT: Liver Tumours	RTT: Liver Transplantation in patients with Acute on Chronic Liver Failure - a call to action	RTT: Actual diagnostic and therapeutic approach to autoimmune and immune-mediated diseases of liver and bile ducts	RTT: Metabolism	RTT: Update on the clinical management of alcoholic liver disease	RTT: Liver Regeneration: From Prometheus to Machines										
8:30 - 9:00																				
9:00 - 9:30																				
9:30 - 10:00	GOOD MORNING EASL																			
10:00 - 10:30		AS: Public Health	HOT TOPICS IN LIVER TRANSPLANTATION II: The successful transplant - Now back to prevention	AS: Viral hepatitis experimental	AS: Controversial topics in Liver Cancer	AS: Experimental cirrhosis and gut-liver axis		AS: NAFLD: Clinical aspects except therapy		AS: Molecular mechanisms of liver disease	MTE: Portopulmonary hypertension - new management	MTE: Treatment of PBC and its extrahepatic manifestations								
10:30 - 11:00																				
11:00 - 11:30																				
11:30 - 12:00	EASL LUNCH TALK: Award Session	ePS: Fibrosis	ePS: Liver dev., physiology and regeneration, experimental liver transplantation and hepatobiliary surgery	ePS: Viral Hepatitis A, B, C, D, E - Virology	ePS: Liver tumours - Experimental and pathophysiology			ePS: NAFLD - Experimental and pathophysiology												
12:00 - 12:30					Clinical state-of-the-art: Immunotherapy in HCC															
12:30 - 13:00	INDUSTRY SATELLITE SYMPOSIA																			
13:00 - 13:30																				
13:30 - 14:00											MTE: Organ allocation: beyond the MELD score	MTE: Wilson's Disease								
14:00 - 14:30		PORTO-SINUSOIDAL VASCULAR DISEASE: what is behind this new name?	EASL-CDC SYMPOSIUM: COVID-19 and the liver - Vaccination, variants and continuity of care	From checkpoint-blockade to immunosuppressants: mgmt. of viral hepatitis in patients with immunomodulators	Managing intrahepatic cholangiocarcinoma	Old and new treatments for patients with advanced cirrhosis	Hepatic manifestations of IgG4-related disease	Novel insights into the pathogenesis of alcoholic liver disease		Liver circadian rhythm										
14:30 - 15:00																				
15:00 - 15:30	EASL MEETS NOBEL PRIZE WINNERS	ePS: Public health	ePS: ALF, DILI, ACLF and critical illness, liver transplantation and hepatobiliary surgery	ePS: Viral hepatitis B/D - Therapy				ePS: NAFLD - Diagnostics and non-invasive assessment												
15:30 - 16:00																				
16:00 - 16:30		GENERAL SESSION I																		
16:30 - 17:00																				
17:00 - 17:30																				
17:30 - 18:00												MTE: Hepatitis C treatment: Are there remaining challenges?	MTE: Screening for liver cancer after hepatitis treatment							
18:00 - 18:30	EASL'S AFTERWORK ROUNDTABLE	INDUSTRY SATELLITE SYMPOSIA																		
18:30 - 19:00																				
19:00 - 19:30																				
19:30 - 20:00																				

	STUDIO	GENERAL HEPATOLOGY		VIRAL HEPATITIS	LIVER TUMOURS	CIRRHOSIS & COMPLICATIONS	IMMUNE-MEDIATED AND CHOLESTATIS	METABOLISM, ALCOHOL & TOXICITY		BASIC SCIENCE	MEET THE EXPERTS	
8:00 - 8:30		AS: Rare liver disease including paediatric and genetic	EASL-ECDC: Inequities in the response to hepatitis elimination in Europe	AS: Liver Immunology		AS: Cirrhosis and portal hypertension		AS: Alcohol-related liver disease	AS: NAFLD - Target identification and drug pipeline	AS: Liver development and regeneration	MTE: Hyperferritinemia	MTE: Link from Adenoma to Liver Cancer. 2021 Update
8:30 - 9:00												
9:00 - 9:30	GOOD MORNING EASL											
9:30 - 10:00												
10:00 - 10:30		How to use statistics for research in liver diseases	Liver disease in pregnancy – challenges and options	Liver disease and the community: Improving liver health in primary care and the community	How do you decide the best 1st and 2nd line option for HCC patients?	Sinusoidal cells in chronic liver disease	EASL-ESCMID: Immunosuppression in Hepatology during the COVID-19 pandemic	EASL-EASD SESSION: NAFLD management in a multidisciplinary team		Liver development	MTE: Abdominal surgery in patients with portal hypertension - Risks and complications	MTE: HBV stopping NUCs before HBs antigens loss
10:30 - 11:00												
11:00 - 11:30										Basic state-of-the-art: Human organoids to model liver diseases		
11:30 - 12:00	EASL LUNCH TALK		ePS: Rare liver diseases (including paediatric and genetic)	ePS: Viral hepatitis C - Clinical aspects except therapy	ePS: Liver tumours - Clinical	ePS: Cirrhosis and its complications - Portal hypertension		ePS: NAFLD - Therapy			MTE: Management of autoimmune hepatitis	MTE: Liver nodules and NAFLD: Search liver nodules and HCC
12:00 - 12:30												
12:30 - 13:00	INDUSTRY SATELLITE SYMPOSIA											
13:00 - 13:30	INDUSTRY SATELLITE SYMPOSIA											
13:30 - 14:00	INDUSTRY SATELLITE SYMPOSIA											
14:00 - 14:30		YOUNG INVESTIGATOR FORUM: lessons learned from the COVID-19 pandemic	EASL-WHO: Interface between non-communicable diseases and liver disease	AS: Hepatitis B: novel therapeutic approaches	AS: Early phase data for novel treatments in Hepatocellular Carcinoma	AS: Complications of cirrhosis	AS: Immune-mediated liver diseases: Clinical aspects	AS: NAFLD: Therapy		AS: Targeting liver inflammation and fibrosis	MTE: Liver diseases in patients with Fontan Surgery	
14:30 - 15:00												
15:00 - 15:30												
15:30 - 16:00				ePS: Viral hepatitis B/D - Clinical aspects except therapy		ePS: Cirrhosis and its complications & Immune-mediated and cholestatic disease - Basic		ePS: Alcohol-related liver disease				
16:00 - 16:30		GENERAL SESSION II									MTE: Liver biofabrication/ tissue engineering	
16:30 - 17:00												
17:00 - 17:30												
17:30 - 18:00												
18:00 - 18:30	EASL'S AFTERWORK ROUNDTABLE											
18:30 - 19:00	INDUSTRY SATELLITE SYMPOSIA											
19:00 - 19:30	INDUSTRY SATELLITE SYMPOSIA											
19:30 - 20:00	INDUSTRY SATELLITE SYMPOSIA											

	STUDIO	GENERAL HEPATOLOGY			VIRAL HEPATITIS	LIVER TUMOURS	CIRRHOSIS & COMPLICATIONS	IMMUNE-MEDIATED AND CHOLESTASIS	METABOLISM, ALCOHOL & TOXICITY	BASIC SCIENCE	MEET THE EXPERTS	
8:00 - 8:30		Genomic editing to treat liver disease			Using existing and novel biomarkers of hepatitis B	EASL-CIRSE-ESGAR: Liver tumour board: Should radioembolisation be included in the guideline?	EASL-ISTH: Vascular liver disease board: DOAC and Liver disease	Pathophysiological aspects of PSC: novel insights	Therapeutic advances in NAFLD		MTE: TIPS: when to use and when not to use	MTE: Mgmt. of fulminant and chronic hepatitis E
8:30 - 9:00												
9:00 - 9:30	GOOD MORNING EASL	ePS: Gut microbiota and liver disease, Molecular and cellular biology	NAF: Case Study - Challenges in person-centred care in cirrhosis		ePS: Viral Hepatitis C - Therapy and resistance, post-SVR and long term follow up		ePS: Cirrhosis and its complications - Other clinical complications except ACLF and critical illness	ePS: Immune-mediated and cholestatic disease - Clinical aspects	ePS: NAFLD - Clinical aspects except therapy			
9:30 - 10:00												
10:00 - 10:30		AS: Impact of the Covid-19 Pandemia on Hepatology	NAF: Oral abstract presentations	Critical reflection on landmark paper 2021	AS: Viral hepatitis clinical management	AS: Liver Tumours Experimental and Pathophysiology	AS: ACLF and liver transplantation		AS: NAFLD: Diagnostics and non-invasive assessment		MTE: Epigenetic (and metagenomics) alterations in liver diseases	MTE: Management of severe alcoholic hepatitis
10:30 - 11:00												
11:00 - 11:30												
11:30 - 12:00	EASL LUNCH TALK WITH EILF	ePS: Imaging and drug targeting & Non-invasive assesment of liver disease except NAFLD		ePS: Immunology							NAF: MTE - The journey of transition for young adults with liver disease/transplantation	
12:00 - 12:30		LATE BREAKER										MTE: Nobel Prize winning CRISPR-Cas-related technologies in modeling human liver disease in mice
12:30 - 13:00												
13:00 - 13:30			ePS: Nurses and Allied Health Professionals research in hepatology									
13:30 - 14:00												
14:00 - 14:30		YOUNG INVESTIGATOR SYMPOSIUM: Translational research in hepatology: the next successful steps	NAF: Symposium - The art and science of collaborative working	EASL-EILF SESSION: Moving forward against all odds	Viral Hepatitis Elimination - Assessing the progress in 2021	Metabolism and cancer	DEBATE IN HEPATOLOGY: Is the term and the concept of ACLF useful in clinical practice?	EASL ESGE: Biliary strictures and what the hepatologist needs to know		In vitro modelling of the human gut-liver axis, including adaptive immune cells	MTE: Novelties and controversial issues of loco-regional treatment for HCC	MTE: Management of recurrent bacterial cholangitis & sclerosing cholangitis of the critically ill patient
14:30 - 15:00												
15:00 - 15:30												
15:30 - 16:00		ILC 2021 WRAP UP SESSION	NAF: "Rising stars" - Encouraging Nurses & AHP's to experience speaking at a European meeting									
16:00 - 16:30												
16:30 - 17:00												
17:00 - 17:30	EASL'S FAREWELL											
17:30 - 18:00												